In a significant development for young Australians living with arthritis, recent updates to the Pharmaceutical Benefits Scheme (PBS) promise to enhance access to crucial medications. This move is particularly beneficial for those grappling with various debilitating health issues, including juvenile arthritis, a rare liver disease, and multiple sclerosis, all of which have now been included in the list of subsidized medicines.
Among these new listings, the expansion of Adalimumab (known as Humira®) to include treatment for juvenile idiopathic arthritis stands out. This medication will not only aid in managing juvenile arthritis but will also be available for other pediatric immune-mediated inflammatory diseases (IMIDs) such as Crohn’s disease, ulcerative colitis, and chronic plaque psoriasis. IMIDs are notorious for causing painful inflammation in the joints, digestive tract, or skin, potentially stunting growth and leading to long-term disabilities.
These health conditions often create significant disruptions in the lives of affected children, hindering their ability to attend school and engage in everyday activities, which puts immense physical, emotional, and financial strain on families. Humira operates by soothing the immune system and diminishing inflammation, thus empowering children to regain their mobility, partake in daily activities, and ultimately improve their quality of life.
It is estimated that between 18,500 and 30,100 Australians aged between 0 and 24 are currently living with some form of arthritis. Health Minister Mark Butler emphasized the importance of the PBS subsidy, stating that without it, patients and their families could face costs nearing $650 for each prescription. "The medicines we’re listing are life-changing for people enduring distressing and potentially fatal conditions," he remarked. Without the PBS, patients would be burdened with expenses that could reach thousands of dollars, whereas under the new scheme, the maximum out-of-pocket expense is now capped at $25 per script, or as little as $7.70 for those with a concession card.
The PBS is widely regarded as one of the most valued government services in Australia, and the government is dedicated to its enhancement by incorporating the latest treatments recommended by medical experts.
In addition to Humira, two other important medications are being introduced to the PBS: Odevixibat and Ublituximab.
Odevixibat (trademarked as Bylvay®) will mark its debut on the PBS, specifically for treating progressive familial intrahepatic cholestasis (PFIC). This group of rare genetic liver disorders primarily affects children but can also impact adults. PFIC leads to the accumulation of bile acids in the liver, resulting in severe itching, sleep disturbances, and progressive liver damage, which may ultimately necessitate a transplant. Bylvay alleviates these symptoms by lowering bile acid levels in the gut, thereby enhancing the well-being of patients and their families. Globally, PFIC is estimated to affect between one in 50,000 to one in 100,000 live births.
Without PBS support, families might face staggering costs exceeding $200,000 for each prescription.
Ublituximab (marketed as Briumvi®) is also being added for the treatment of relapsing-remitting multiple sclerosis (RRMS) for the first time. RRMS is an autoimmune disorder that inflicts damage on the central nervous system, often leading to severe symptoms and long-lasting disability. It can drastically impair an individual's mobility, vision, and overall independence. Briumvi targets the B-cells responsible for inflammation in multiple sclerosis, helping to reduce relapse rates, slow disease progression, and enhance the quality of life for those affected. In 2024, over 14,000 patients accessed a similar treatment through the PBS, an essential resource considering that, without the subsidy, they could face costs of around $15,000 per prescription.
The PBS is a fundamental element of the Australian Government’s broader National Medicines Policy, designed to fulfill the medication and related service needs essential for achieving optimal health outcomes while also meeting economic goals. Under this scheme, the government subsidizes medication for numerous medical conditions, allowing many listed medicines to be dispensed by pharmacists and utilized by patients at home.
Since its inception as a limited program in 1948—initially providing free medications to pensioners and a list of 139 vital medicines that were available at no charge—the PBS has evolved considerably. Today, it boasts over 900 listed medicines, encompassing more than 5,000 distinct brands. The PBS Schedule details all the medications available for patient dispensing at a government-subsidized price and is overseen by the Department of Health, Disability and Ageing, with administration carried out by Services Australia.
